Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers-Reference-Cited by-同舟云学术

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Published:2013-09-23 Issue:5 Volume:15 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Bianchini Giampaolo,Pusztai Lajos,Karn Thomas,Iwamoto Takayuki,Rody Achim,Kelly Catherine M,Müller Volkmar,Schmidt Marcus,Qi Yuan,Holtrich Uwe,Becker Sven,Santarpia Libero,Fasolo Angelica,Del Conte Gianluca,Zambetti Milvia,Sotiriou Christos,Haibe-Kains Benjamin,Symmans W Fraser,Gianni Luca

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr3481.pdf

Reference35 articles.

1. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE: Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 2012, 30: 718-721. 10.1200/JCO.2010.34.4010.

2. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Rajan B, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013, 381: 805-816. 10.1016/S0140-6736(12)61963-1.

3. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A: Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011, 103: 1299-1309. 10.1093/jnci/djr242.

4. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010, 11: 55-65. 10.1016/S1470-2045(09)70314-6.

5. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010, 16: 5222-5232. 10.1158/1078-0432.CCR-10-1282.

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients;Breast Cancer Research and Treatment;2024-05-06

2. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer;JAMA Network Open;2023-12-28

3. Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy;British Journal of Cancer;2023-11-07

4. Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer;JAMA Network Open;2023-08-30

5. Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial;European Journal of Cancer;2023-06